The Anticoagulant Effect of Heparinoid Org 10172 During Haemodialysis: An Objective Assessment

Summary

The heparinoid of natural origin Org 10172 has anti-factor Xa activity but minimal anti-thrombin activity, and little effect upon broad spectrum assays such as the KCCT in vitro. Its anticoagulant effects have been compared to those of commercial heparin in 7 patients undergoing haemodialysis for chronic renal failure. Commercial heparin was administered in a dose (5,000 iu bolus + 1,500 iu/hour continuous iv infusion) previously shown to inhibit fibrin formation during haemodialysis. This produced mean anti-factor Xa levels in plasma between 0.7-1.0 iu/ml and largely suppressed fibrin formation for 5 h dialysis measured as mean FPA levels in plasma. Administration of Org 10172 as a bolus of 1,350 anti-factor Xa u or 2,000-2,400 anti-factor Xa u produced plasma anti-factor Xa levels of less than 0.5 u/ml and allowed fibrin clot and FPA generation during dialysis. Org 10172 administered as a bolus dose of 4,000-4,800 anti-factor Xa u produced mean anti-factor Xa levels of greater than 0.5 u/ml, allowed dialysis of 6 patients for 5 h and appreciably suppressed FPA generation during dialysis, with little effect on the KCCT.

It is concluded that the anti-factor Xa activity of Org 10172 may reflect its ability to inhibit fibrin during dialysis and that single bolus injection of Org 10172 may be a useful alternative method of achieving anticoagulation.

Key words

Fibrinopeptide A - Heparinoid Org 10172 - Haemodialysis

• References

• 1 Nossel HL, Yudelman I, Canfield RE, Butler VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
• 2 Ireland H, Lane DA, Curtis JR. Objective assessment of heparin requirements for haemodialysis in humans. J Lab Clin Med 1984; 103: 643-652
• 3 Lane DA, Michalski R, VanRoss M, Kakkar VV. Comparison of heparin and a semi-synthetic heparin analogue, A73025.1. Kinetics of clearance from the circulation of man following intravenous injection. Brit J Haematol 1977; 37: 239-245
• 4 Michaelski R, Lane DA, Kakkar VV. Comparison of heparin and a semi-synthetic heparin analogue, A73025. II. Some effects upon platelet function. Brit J Haematol 1977; 37: 247-256
• 5 Fisher AM, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate (SP54) and heparin I: Mechanism of action on blood coagulation. Thromb Haemostas 1982; 47: 104-108
• 6 Ofosu FA, Blajchman MA, Modi GJ, Smith LM, Buchanan MR, Hirsh J. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate. Brit J Haematol 1985; 60: 695-704
• 7 Scully MF, Kakkar VV. Effect of a pentosan polysulphate upon thrombin and factor Xa inactivation by antithrombin III. Biochem J 1984; 222: 571-578
• 8 Meulemann DG, Hobbelen PM J, van Deden G, Moelker HC T. A novel antithrombic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models. Thromb Res 1982; 27: 353-363
• 9 Buller HR, Hobbelen PM J, Princen AW N, Moelker HC T, Ten Cate JW. The effects of high plasma antithrombin III levels in the presence and absence of heparin on the bleeding tendency using an experimental model in rats. Observations on a novel natural heparinoid (Org 10172). Thromb Res 1983; 31: 787-797
• 10 Morrison P, Magnani HN. Org 10172, a low molecular weight heparinoid, its pharmacology and pharmokinetics in healthy volunteers. In “Report of the 3rd Amstol Symposium”, Amsterdam. Publ. KabiVitrum Diagnostica and Sanofi-Labaz; pp 142-145 1982
• 11 Henny ChP, Ten Cate H, Ten Cate JW, Surachno S, Bronswijk HV, Wilmink JM, Ockelford PA. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet 1983; 1: 890-893
• 12 Ten Cate H, Henny ChP, Ten Cate JW, Buller HR, Mooy MC, Surachno S, Wilmink JM. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients. Thromb Res 1985; 38: 211-222
• 13 Lane DA, Ireland H, Flynn A, Anastassiades E, Curtis JR. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation. Submitted for publication
• 14 Denton J, Lane DA, Thunberg L, Slater AM, Lindahl U. Binding of platelet factor 4 heparin oligosaccharides. Biochem J 1983; 209: 455-460
• 15 Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-732
• 16 Ludlam CA, Moore S, Bolton AE, Pepper DS, Cash JD. The release of a human platelet specific protein measured by a radioimmunoassay. Thromb Res 1975; 6: 543-548
• 17 Lane DA, Ireland H, Wolff S, Grant R, Jennings S, Allen-Mersh T. Plasma concentrations of fibrinopeptide A, fibrinogen fragment BB1-42 and B thromboglobulin following total hip replacement. Thromb Res 1982; 26: 111-118
• 18 Ireland H, Lane DA, Wolff S, Foadi M. In vivo platelet release in myeloproliferative disorders. Thromb Haemostas 1982; 48: 41-45
• 19 Lane DA, Ireland H, Knight I, Wolff S, Kyle P, Curtis J. The significance of fibrinogen derivatives in plasma in human renal failure. Brit J Haematol 1984; 56: 251-260
• 20 Lane DA, Siodlak M, Thompson E, Allen-Mersh TE. Clearance of human desaminotyrosyl fibrinopeptide A from the rat circulation: role of kidney and proteolytic enzymes. Thromb Res 1982; 26: 73-82